Nutritional Advice El Mondo
Objectives:
What is the immunogenicity and safety of the 7 different Ebola virus vaccines in healthy adults?
Study design:
This review article included 21 randomized controlled trials (RCTs), evaluating 7 different vaccines with different doses with a total of 5,275 participants.
Results and conclusions:
The investigators found the rVSVΔG-ZEBOV-GP (2 × 107) vaccine was more immunogenic [p-score = 0.80].
The investigators found for pain, rVSVΔG-ZEBOV-GP (≤105) had few events [p-score = 0.90].
The investigators found for fatigue and headache, the DNA-EBOV (≤ 4 mg) was the best one with [p-scores of 0.94 and 0.87], respectively.
The investigators found for myalgia, the ChAd3 (1010) had a lower risk [p-score = 0.94].
The investigators found for fever, the Ad5.ZEBOV (≤ 8 × 1010) was the best one [p-score 0.80].
The investigators concluded that the best vaccine to be used to stop future outbreak of Ebola is the rVSVDG-ZEBOV-GP vaccine at dose of 2 × 107 plaque-forming units (PFU).
Original title:
Immunogenicity and safety of Ebola virus vaccines in healthy adults: a systematic review and network meta-analysis by Diallo A, Carlos-Bolumbu M, […], Galtier F.
Link:
https://pubmed.ncbi.nlm.nih.gov/34270366/
Additional information of El Mondo:
Find more information/studies on RCTs/cohort/significantly/review article, vaccination and food fortification/malnutrition right here.
Ebola virus disease (EVD), formerly known as Ebola haemorrhagic fever, is a rare but severe, often fatal illness in humans and is been caused by the Ebola virus. As the Ebola virus spreads through the body, it damages the immune system and organs. Ultimately, it causes levels of blood-clotting cells to drop. This leads to severe, uncontrollable bleeding.
The Ebola virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission.
The average Ebola virus disease case fatality rate is around 50%.
The Ebola virus was first discovered in 1976 near the Ebola River in what is now the Democratic Republic of Congo.
Recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV), also known as Ebola Zaire vaccine live and sold under the brand name Ervebo, is an Ebola vaccine for adults (18 years and older) that prevents Ebola caused by the Zaire ebolavirus. Ervebo contains a virus known as vesicular stomatitis virus which has been weakened and modified to contain a protein from the Zaire Ebola virus.